ENABLEX has been administered in clinical trials at doses up to 75 mg (five times maximum therapeutic dose). The most common adverse events seen were dry mouth, constipation, headache, dyspepsia and nasal dryness. However, overdosages with darifenacin can potentially lead to severe anticholinergic effects and should be treated accordingly. Therapy should be aimed at reversing the anticholinergic symptoms under careful medical supervision. The use of agents such as physostigmine can assist in reversing such symptoms.